News | March 06, 2014

Drug-eluting Balloon Angioplasty Useful in Diabetic Population

Drug-eluting Balloon Angioplasty Clinical Study Trial Diabetes Restenosis

March 6, 2014 — Despite good immediate results, in up to 40 percent of patients, obstructed arteries in the leg treated with a stent will again become blocked. This in-stent restenosis is typically treated with balloon angioplasty to clear the artery. The addition of drug-eluting balloons is showing improved outcomes for restenosis and could become the treatment of choice for femoropopliteal in-stent restenosis.

The Journal of Endovascular Therapy offers results of a prospective study seeking to establish the rate of one-year restenosis in diabetic patients with femoropopliteal in-stent restenosis who underwent treatment with drug-eluting balloon angioplasty. The study is known as Drug-Eluting Balloon in Peripheral Intervention for In-Stent Restenosis, or DEBATE–ISR.

Conventional treatment of restenosis in femoral and popliteal arteries relies on repeat high-pressure dilation with balloons, which has a high rate of recurrent restenosis. The drug-eluting balloon delivers paclitaxel as it expands within the stent. Paclitaxel is an antiproliferative drug that inhibits microtube formation and subsequent ingrowth of smooth muscle cells.

In this study, 44 diabetic patients were treated for femoropopliteal in-stent restenosis with the drug-eluting balloon. After one year, their recurrent restenosis rate was compared with that of a control group—42 diabetic patients previously treated with standard balloon angioplasty for in-stent restenosis.

A significant reduction in restenosis was achieved. Study results show that only 19.5 percent of patients treated with the drug-eluting balloon experienced recurrent restenosis after one year, whereas those treated with standard balloon angioplasty had a 71.8 percent rate of recurrence. Additionally, only 13.6 percent of patients in the drug-eluting balloon treatment group underwent target lesion revascularization compared with 31 percent of those in the control group.

These results offer reassurance to physicians about the safety of this procedure. They also put forward a promising alternative to the other restenosis technologies and strategies that have shown mixed outcomes.

An accompanying commentary notes that while further studies are needed, these results are encouraging. The authors point out the limitations of the study, including the absence of randomization and use of the historical control group. However, they state that the results for these diabetic patients “are particularly impressive in light of the high-risk patient population being treated.”

For more information: jevt.org

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init